Cargando…
Cyclophosphamide depletes tumor infiltrating T regulatory cells and combined with anti-PD-1 therapy improves survival in murine neuroblastoma
The outcome for children with high-risk neuroblastoma is poor despite intensive multi-modal treatment protocols. Toxicity from current treatments is significant, and novel approaches are needed to improve outcome. Cyclophosphamide (CPM) is a key component of current chemotherapy regimens and is know...
Autores principales: | Webb, Emily R., Moreno-Vincente, Julia, Easton, Alistair, Lanati, Silvia, Taylor, Martin, James, Sonya, Williams, Emily L., English, Vikki, Penfold, Chris, Beers, Stephen A., Gray, Juliet C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9463572/ https://www.ncbi.nlm.nih.gov/pubmed/36097618 http://dx.doi.org/10.1016/j.isci.2022.104995 |
Ejemplares similares
-
Immune characterization of pre-clinical murine models of neuroblastoma
por: Webb, Emily R., et al.
Publicado: (2020) -
Fc-null anti-PD-1 monoclonal antibodies deliver optimal checkpoint blockade in diverse immune environments
por: Moreno-Vicente, Julia, et al.
Publicado: (2022) -
Cyclophosphamide in combination with tumor lysate and TLR9 ligand regresses murine neuroblastoma
por: Gershan, Jill, et al.
Publicado: (2013) -
Immune modulating effects of cyclophosphamide and treatment with tumor lysate/CpG synergize to eliminate murine neuroblastoma
por: Gershan, Jill A., et al.
Publicado: (2015) -
Molecular Iodine/Cyclophosphamide Synergism on Chemoresistant Neuroblastoma Models
por: Álvarez-León, Winniberg, et al.
Publicado: (2021)